- Home
- CON vs MLTX Comparison
CON vs MLTX Comparison
Compare CON & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CON
- MLTX
- Stock Information
- Founded
- CON 1979
- MLTX 2021
- Country
- CON United States
- MLTX Switzerland
- Employees
- CON N/A
- MLTX N/A
- Industry
- CON
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- CON
- MLTX Health Care
- Exchange
- CON NYSE
- MLTX Nasdaq
- Market Cap
- CON 2.7B
- MLTX 2.8B
- IPO Year
- CON 2024
- MLTX N/A
- Fundamental
- Price
- CON $20.56
- MLTX $48.89
- Analyst Decision
- CON Strong Buy
- MLTX Strong Buy
- Analyst Count
- CON 7
- MLTX 7
- Target Price
- CON $29.00
- MLTX $73.33
- AVG Volume (30 Days)
- CON 895.0K
- MLTX 504.0K
- Earning Date
- CON 07-31-2025
- MLTX 08-06-2025
- Dividend Yield
- CON 1.22%
- MLTX N/A
- EPS Growth
- CON N/A
- MLTX N/A
- EPS
- CON 1.30
- MLTX N/A
- Revenue
- CON $1,933,346,000.00
- MLTX N/A
- Revenue This Year
- CON $13.09
- MLTX $103.42
- Revenue Next Year
- CON $7.35
- MLTX N/A
- P/E Ratio
- CON $15.79
- MLTX N/A
- Revenue Growth
- CON 4.54
- MLTX N/A
- 52 Week Low
- CON $18.89
- MLTX $31.42
- 52 Week High
- CON $24.81
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- CON N/A
- MLTX 66.20
- Support Level
- CON N/A
- MLTX $46.24
- Resistance Level
- CON N/A
- MLTX $48.72
- Average True Range (ATR)
- CON 0.00
- MLTX 1.54
- MACD
- CON 0.00
- MLTX 0.16
- Stochastic Oscillator
- CON 0.00
- MLTX 94.34
About CON CONCENTRA GROUP HOLDINGS PARENT INC
Concentra Group Holdings Parent Inc is a provider of occupational health services in the United States. The business is organized into three operating segments: occupational health centers, onsite health clinics, and other businesses.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.